Schonfeld Strategic Advisors LLC Has $1.94 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Schonfeld Strategic Advisors LLC lowered its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 32.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 205,702 shares of the biopharmaceutical company's stock after selling 97,156 shares during the quarter. Schonfeld Strategic Advisors LLC owned approximately 0.07% of Amicus Therapeutics worth $1,938,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of FOLD. Covestor Ltd lifted its holdings in shares of Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 2,312 shares in the last quarter. R Squared Ltd acquired a new position in shares of Amicus Therapeutics in the 4th quarter valued at about $79,000. Virtu Financial LLC purchased a new stake in shares of Amicus Therapeutics in the third quarter worth approximately $107,000. KBC Group NV boosted its holdings in shares of Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after purchasing an additional 3,120 shares during the period. Finally, Sciencast Management LP purchased a new position in Amicus Therapeutics during the fourth quarter valued at approximately $100,000.

Amicus Therapeutics Price Performance

Shares of FOLD stock traded down $0.10 during mid-day trading on Friday, reaching $5.98. The company's stock had a trading volume of 8,856,089 shares, compared to its average volume of 2,760,150. The company has a market cap of $1.84 billion, a P/E ratio of -33.22, a PEG ratio of 1.51 and a beta of 0.64. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. Amicus Therapeutics, Inc. has a 1-year low of $5.82 and a 1-year high of $12.65. The firm's 50-day moving average is $7.65 and its two-hundred day moving average is $9.09.

Analysts Set New Price Targets

FOLD has been the topic of several research analyst reports. UBS Group boosted their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday, May 2nd. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Wells Fargo & Company decreased their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Finally, The Goldman Sachs Group lowered their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.